Micronization is the process of reducing the average diameter of the particles of a solid material, typically into the micrometre range and in some cases the nanometre range. It is a form of comminution and is a critical unit operation in the manufacture of active pharmaceutical ingredients, food ingredients, pigments, agrochemicals and other fine chemicals where dissolution rate, content uniformity or aerosol behaviour depend on particle size.
Industrial micronization is carried out by several distinct technology families. Mechanical comminution methods — particularly air-jet milling and cryogenic milling — dominate commercial pharmaceutical production and operate under current good manufacturing practice regulations such as ICH Q7. For sub-micron particles required by poorly water-soluble drugs, wet bead milling, high-pressure homogenization and dry co-milling produce nanocrystalline suspensions and powders. Supercritical fluid precipitation methods, including RESS, SAS and PGSS, offer finer morphological control for thermolabile compounds.
The principal rationale for micronization in pharmaceutical applications is the inverse relationship between particle diameter and surface area in the Noyes–Whitney equation: reducing particle size accelerates dissolution and, for poorly soluble drugs in BCS Class II and IV, can substantially improve bioavailability. Other major applications include dry powder and metered-dose inhaler formulations, where aerodynamic diameter in the 1–5 μm range is required for lung deposition. Particle size after micronization is most commonly measured by laser diffraction under USP general chapter <429> and the harmonized ISO 13320 standard, and reported as the volume-weighted D10, D50 and D90 statistics.
High-energy mechanical micronization can introduce surface amorphization, polymorphic conversion and triboelectric charging, all of which affect downstream stability and processability and often require post-milling conditioning to control.
Mechanics of Micronization
The size reduction achieved by mechanical micronization depends on both the mill and the material being ground. The breakage behaviour of a material can be characterised by material parameters derived from single-particle impact tests, which quantify a particle's resistance to fracture and the minimum specific energy it can absorb without breaking; these allow the breakage probability of different materials to be described by a common master curve.
Mechanical comminution Mechanical comminution is the dominant family of techniques for industrial micronization. The process typically begins with coarse size reduction — crushing by hammer or impact mills and cutting by blade mills — which produces feed material in the millimetre-to-coarse-micrometre range from bulk solids. Conventional tumbling ball mills, in which a rotating drum loaded with steel or ceramic grinding media reduces the feed by impact and abrasion, are widely used for grinding in the 50–500 μm range but do not typically achieve micrometre-scale particle sizes on their own. True micronization to the 1–10 μm range is achieved by higher-energy mechanical techniques, principally jet milling for dry powders and wet bead milling or high-pressure homogenization for aqueous suspensions, which are described in the following sections.
Industrial pharmaceutical micronization is dominated by mechanical comminution methods, particularly air-jet milling (also called fluid energy milling) and cryogenic milling. These mechanical methods scale from gram-level development batches to multi-metric-ton commercial campaigns and operate under current good manufacturing practice (cGMP) regulations such as 21 CFR Part 211 and ICH Q7.
The choice of micronization technology depends on the active pharmaceutical ingredient's physical properties. Air-jet milling produces narrow, log-normal particle-size distributions typically with D50 below 5 µm and span ≤ 2, and is the standard approach for dry powder inhalation products and poorly soluble oral solids. Cryogenic milling is used for heat-sensitive and elastic compounds where ambient-temperature jet milling would cause thermal degradation or insufficient particle breakage.
Jet milling Jet milling (also called fluid energy milling) is the most widely used industrial technique for micronizing active pharmaceutical ingredients and similar fine chemicals. Unlike ball or media mills, jet mills contain no moving grinding bodies; particle size reduction is achieved by high-velocity particle–particle collisions in a stream of compressed gas, typically nitrogen or dry air.
In a fluid energy (jet) mill, particles are entrained in one or more high-velocity gas streams and size reduction occurs primarily through collisions between the particles themselves rather than impact with the mill walls, which minimises contamination; the cooling produced by expansion of the compressed gas also permits the milling of heat-sensitive materials. Spiral jet mills, which have no moving parts, are widely used to micronize pharmaceutical substances to narrow size distributions in the low-micrometre range.
The most common configuration is the spiral jet mill (also called a pancake or loop mill), in which feed material is introduced into a flat cylindrical chamber through a Venturi and accelerated by tangential gas jets. Coarse particles are retained near the chamber wall by centrifugal force and continue to be ground, while fines exit through a central classifier outlet. Spiral jet mills routinely achieve volume median diameters (D50) of 1–10 μm without product contact with mechanical grinding surfaces, making the technology attractive for high-purity and abrasion-sensitive materials.
The principal process parameters are grinding gas pressure, feed rate, and the ratio between them; increasing pressure or decreasing feed rate generally shifts the particle size distribution finer. Because the expanding gas cools as it leaves the nozzles, jet milling imparts much less thermal stress than mechanical mills, allowing micronization of thermolabile and low-melting actives. However, the high specific energy input can induce surface amorphization, lattice strain, and changes in surface energy that affect downstream processability and stability.
For highly potent compounds — such as steroidal hormones, cytotoxic oncology actives, and antibody–drug conjugate payloads — jet mills are operated inside containment isolators meeting occupational exposure limits in the nanogram-per-cubic-metre range. Methods like crushing and cutting are also used for reducing particle diameter, but produce more rough particles compared to the two previous techniques (and are therefore the early stages of the micronization process). Crushing employs hammer-like tools to break the solid into smaller particles by means of impact. Cutting uses sharp blades to cut the rough solid pieces into smaller ones.
In pharmaceutical jet milling, the specific energy (energy input per unit mass of feed) is the principal factor governing the resulting particle size and is used as the basis for scaling the process from laboratory to commercial manufacture.
Wet media milling (nanocrystal technology) In wet media milling, the drug substance is suspended in an aqueous solution containing a stabilizing surfactant or polymer and circulated through a chamber filled with small (typically 0.2–0.5 mm) ceramic, glass, or polymer-coated beads. Bead-on-bead and bead-on-particle impacts progressively reduce the drug particle size to the 100–400 nm range, while the stabilizer adsorbs onto newly created surfaces and prevents agglomeration.
The technology, commercialized as NanoCrystal by Elan Drug Technologies (later Alkermes), underpins several U.S. Food and Drug Administration–approved products, including sirolimus (Rapamune oral tablet, approved 2000), aprepitant (Emend, 2003), fenofibrate (Tricor 145 mg, 2004; Triglide, 2005), and megestrol acetate (Megace ES, 2005).
High-pressure homogenization In high-pressure homogenization (HPH), a coarse drug suspension is forced at pressures of 100–2000 bar through a narrow gap (typically a few micrometres wide), where particles are disintegrated by cavitation, shear, and particle–particle collisions. The technique can be operated in water (DissoCubes platform) or in non-aqueous or water-reduced media (Nanopure platform), the latter being useful for hydrolytically unstable compounds.
Unlike dry jet milling, both wet milling and HPH yield aqueous nanosuspensions that can be dosed directly as liquids or converted to solid dosage forms by spray drying, freeze drying, or granulation. Both technologies are scalable to commercial volumes and are compatible with cGMP aseptic processing for parenteral products.
Dry co-micronization Dry co-micronization is a nanomilling approach in which the drug substance is milled in a dry state together with GRAS excipients in a single unit operation. The excipients form a protective dispersion matrix around the sub-micron drug particles, preventing the surface-energy-driven reaggregation that otherwise dominates dry submicron powders, and yielding a free-flowing powder that can be tableted or encapsulated without further drying or downstream processing.
The most widely commercialized dry co-micronization platform is SoluMatrix Fine Particle Technology, developed by iCeutica and acquired in 2011 by Iroko Pharmaceuticals. The platform has been used to formulate three U.S. Food and Drug Administration–approved low-dose non-steroidal anti-inflammatory drugs: Zorvolex (diclofenac, approved October 2013), Tivorbex (indomethacin, approved February 2014), and Vivlodex (meloxicam, approved October 2015). Each product was approved at a total daily dose 20–35% below the equivalent conventionally-formulated NSAID, on the basis that the increased dissolution rate of sub-micron particles permits comparable analgesic efficacy at lower systemic exposure.
Unlike wet media milling, dry co-micronization requires no aqueous suspension or downstream drying step, shortening the unit-operation chain at the cost of constraining the formulation to excipients compatible with high-energy dry impact.
Supercritical fluid methods Supercritical fluid precipitation techniques produce micronized particles by inducing supersaturation in a supercritical-fluid solution, leading to controlled precipitation of individual particles. The three most widely applied variants are the RESS process (Rapid Expansion of Supercritical Solutions), the SAS method (Supercritical Anti-Solvent) and the PGSS method (Particles from Gas Saturated Solutions), each described in the subsections below.
Supercritical carbon dioxide (scCO2) is the most commonly used medium because it is chemically inert, has easily accessible critical-point parameters, and can be used to obtain either crystalline or amorphous micronized forms.
Particle size and morphology are controlled both by macroscopic parameters such as nozzle geometry and flow rate, and by molecular-level effects of pressure, temperature, solute concentration and antisolvent-to-solvent ratio. These conditions influence nucleation kinetics and can drive polymorphic or amorphous transformations during particle formation.
Compared to mechanical comminution, supercritical-fluid methods generally yield narrower particle-size distributions and more consistent particle morphology, and the relatively mild operating pressures and temperatures permit processing of thermolabile compounds. The use of CO2 as solvent also avoids the flammable and toxic organic solvents required by some conventional precipitation methods.
RESS